PMID- 26603006
OWN - NLM
STAT- MEDLINE
DCOM- 20160425
LR  - 20160815
IS  - 1806-9282 (Electronic)
IS  - 0104-4230 (Linking)
VI  - 61
IP  - 5
DP  - 2015 Sep-Oct
TI  - Brachytherapy and radical prostatectomy in patients with early prostate cancer.
PG  - 431-9
LID - S0104-42302015000500431 [pii]
LID - 10.1590/1806-9282.61.05.431 [doi]
AB  - OBJECTIVE: this study analyzes the survival of prostate cancer patients cared for 
      at a hospital in Minas Gerais, Brazil according to one of the following 
      treatments: iodine-125 seed implantation or radical prostatectomy. From January 
      2002 to December 2005, 129 patients underwent either brachytherapy (64 patients) 
      or surgery (65 patients). METHODS: all had prostate-specific antigen, Gleason 
      scores and clinical stage recorded prior to treatment. Biochemical relapse was 
      defined as prostate-specific antigen (PSA)>0.4 ng/mL for radical prostatectomy, 
      and any elevation equal or higher than 2 ng/mL over the PSA nadir for implanted 
      patients. To analyze the effect of treatment on biochemical recurrence-free 
      survival (BRFS), Kaplan-Meier curves and Cox regression were generated. Mean 
      follow-up time was 56.1 months for patients with the implant, and 26.6 months for 
      those operated on. BRFS in 5 years was 69% (95% CI: 58.18-77.45) for the whole 
      cohort. DISCUSSION: when stratified according to treatment, survival of patients 
      who had undergone brachytherapy (79.70%) was higher to those operated on (44.30%; 
      p value= 0.0056). Upon multivariate analysis, independent predictors were iPSA 
      (HR: 2.91, 95% CI: 1,32-6,42), Gleason score (HR: 2.18, 95% CI: 1,00-4,81) and 
      treatment modality (HR: 2.61, 95% CI: 1.18-5,75). Risk of biochemical failure was 
      higher with surgery than brachytherapy, which may be related to the failure 
      criteria adopted, which is different for each therapy, as well as the high rate 
      of histological progression between preoperative prostate biopsy and surgical 
      specimen. CONCLUSION: it was found that brachytherapy is a good therapeutic 
      option for low risk prostate cancer.
FAU - Ferreira, Adriana Souza Sergio
AU  - Ferreira AS
AD  - Oncology Service, Hospital Universitario, Universidade Federal de Juiz de Fora, 
      Juiz de Fora, MG, Brazil.
FAU - Guerra, Maximiliano Ribeiro
AU  - Guerra MR
AD  - Department of Collective Health, Universidade Federal de Juiz de Fora, Juiz de 
      Fora, MG, Brazil.
FAU - Lopes, Humberto Elias
AU  - Lopes HE
AD  - Department of Surgery, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, 
      Brazil.
FAU - Lima, U-Thant Mendonca
AU  - Lima UT
AD  - Radiotherapy Service, Hospital Ascomcer, Juiz de Fora, MG, Brazil.
FAU - Vasconcelos, Yara Abrao
AU  - Vasconcelos YA
AD  - Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil.
FAU - Teixeira, Maria Teresa Bustamante
AU  - Teixeira MT
AD  - Department of Collective Health, Universidade Federal de Juiz de Fora, Juiz de 
      Fora, MG, Brazil.
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Rev Assoc Med Bras (1992)
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
RN  - 0 (Iodine Radioisotopes)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Brachytherapy/*methods
MH  - Cohort Studies
MH  - Disease-Free Survival
MH  - Follow-Up Studies
MH  - Humans
MH  - Iodine Radioisotopes/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prostate-Specific Antigen/blood
MH  - Prostatectomy/*methods
MH  - Prostatic Neoplasms/pathology/*therapy
MH  - Risk Assessment
MH  - Survival Analysis
EDAT- 2015/11/26 06:00
MHDA- 2016/04/26 06:00
CRDT- 2015/11/26 06:00
PHST- 2014/07/16 00:00 [received]
PHST- 2014/07/23 00:00 [accepted]
PHST- 2015/11/26 06:00 [entrez]
PHST- 2015/11/26 06:00 [pubmed]
PHST- 2016/04/26 06:00 [medline]
AID - S0104-42302015000500431 [pii]
AID - 10.1590/1806-9282.61.05.431 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras (1992). 2015 Sep-Oct;61(5):431-9. doi: 
      10.1590/1806-9282.61.05.431.